Browse
Submit Data
Databases
API
Help

Dataset Information

34 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Phase II Study of Panitumumab with Fluorouracil in Patients With KRAS Wild-type Metastatic Colorectal Cancer(PF Study)

ABSTRACT: Interventions: l-LV 200mg/m2 day 1 5-FU/bolus 400mg/m2 day1 5-FU/infusional 2,400mg/m2 day1-2 Panitumumab 6mg/kg day 1 Biweekly or Capecitabine 2,000mg/m2/day day1-7 Panitumumab 6mg/kg day1 Biweekly or S-1 80mg/m2/day day1-7 Panitumumab 6mg/kg day1 Biweekly or UFT 300mg/m2/day day1-7 LV 75 mg/m2/day day1-7 Panitumumab 6mg/kg day1 Biweekly Primary outcome(s): Response rate Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2622610 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Multicenter Phase II Study of Panitumumab and Irinotecan with or without Fluoropyrimidines in patients with KRAS Wild-type Metastatic Colorectal Cancer (PACIFIC)

Project description:Interventions: Irinotecan 150 mg/m2/biweekly div l-LV 200mg/m2/biweekly div 5-FU/bolus 400mg/m2/biweekly div (bolus) 5-FU/infusional 2,400mg/m2/biweekly div Panitumumab 6mg/kg/biweekly div or S-1 80mg/m2/day p.o. day 1-7 Irinotecan 150mg/m2 day 1 Panitumumab 6mg/kg/biweekly div Irinotecan 150mg/m2/ biweekly div Panitumumab 6mg/kg/biweekly div Primary outcome(s): Progression-free survival Study Design: Parallel Randomized

| 2623074 | ecrin-mdr-crc

Neoaduvant chemotherapy woth FOLFOXIRI and anti-EGFR monoclonal antibody for colorectal cancer with liver metastasis

Project description:Interventions: day1:CPT-11(150mg/m2),L-OHP(65mg/m2),L-LV(200mg/m2) day1-2:5-FU(3200mg/m2)48hr civ, day1:Panitumumab(6mg/kg) or day1 and 7 cetuximab(400mg/m2) ever 2 weeks Primary outcome(s): R0 rejective rate Study Design: Single arm Non-randomized

| 2620819 | ecrin-mdr-crc

study of medical treatment reactivity by the chemokine receptor (CXCR4)as 1st line treatment in patients with metastatic colorectal cancer

Project description:Interventions: CXCR4-CEC>=20 mFOLFOX6,Bevacizumab L-OHP:85mg/m2 5-FU(bolus):400mg/m2 l-LV:200mg/m2 5-FU(infusion):2,400mg/m2 Bevacizumab:5mg/m2 CXCR4-CEC>=20 mFOLFOX6,Panitumumab L-OHP:85mg/m2 5-FU(bolus):400mg/m2 l-LV:200mg/m2 5-FU(infusion):2,400mg/m2 Panitumumab :6mg/m2 CXCR4-CEC<20 mFOLFOX6,Bevacizumab L-OHP:85mg/m2 5-FU(bolus):400mg/m2 l-LV:200mg/m2 5-FU(infusion):2,400mg/m2 Bevacizumab:5mg/m2 CXCR4-CEC<20 mFOLFOX6,Panitumumab L-OHP:85mg/m2 5-FU(bolus):400mg/m2 l-LV:200mg/m2 5-FU(infusion):2,400mg/m2 Panitumumab :6mg/m2 Primary outcome(s): Progression-free survival Study Design: Parallel Randomized

| 2623948 | ecrin-mdr-crc

Investigation of usability of combination therapy with S-1 plus panitumumab in patients with KRAS wild type unresectable advanced and recurrent colorectal cancer, who had previously received on fluoropyrimidine, oxaliplatin and irinotecan ; phase II study.

Project description:Interventions: Panitumumab/S-1 combination therapy Panitumumab 6mg/kg, biweekly S-1 80mg/m2/day, po from day 1 to 28 of each 42 days cycle Primary outcome(s): Progression free survival (PFS) Study Design: Single arm Non-randomized

| 2622693 | ecrin-mdr-crc

Phase II clinical trial of Cetuximab with Fluorouracil therapy for patients refractory or intolerable to Oxaliplatin and Irinotecan with KRAS wild-type unresectable/recurrent colorectal cancer

Project description:Interventions: (Cetuximab with Fluorouracil therapy) Cetuximab=400mg/m2 (day1)Cetuximab=250mg/m2/weekly(day 8-) with 1) l-LV=200mg/m2/bi-week 5-FU/bolus=400mg/m2/bi-week 5-FU/infusional=2,400mg/m2/bi-week (day1-3) 2) LV=75mg/day (*Administration for 4weeks and Drug withdrawal for one week)UFT=300-600mg/day* 3) Capecitabine=2,000mg/m2/day(*Administration for 2weeks and Drug withdrawal for one week) 4) S-1=80-120mg/day (*Administration for 2weeks and Drug withdrawal for one week) Primary outcome(s): Progression-free survival; PFS Study Design: Single arm Non-randomized

| 2623785 | ecrin-mdr-crc

Multicenter Phase II Study of FOLFOX Plus Bi-weekly Cetuximab as First Line Treatment in Patients with Metastatic Colorectal Cancer

Project description:Interventions: Chemotherapy regimen mFOLFOX6 +Cetuximab Cetuximab 500mg/m2/biweekly Oxaliplatin 85mg/m2/biweekly l-LV 200mg/m2/biweekly 5-FU/bolus 40mg/m2/biweekly 5-FU/infusional 2400mg/m2/biweekly ( day1-3:46h) Primary outcome(s): Response Rate Study Design: Single arm Non-randomized

| 2621834 | ecrin-mdr-crc

Multicenter randomized phase ll study of XELOX plus bevacizumab or XELIRI plusbevacizumab as first-line chemotherapy for metastatic or recurrent colorectal cancer

Project description:Interventions: XELOX plus bevacizumab therapy Bevacizumab 7.5mg/kg day1 Oxaliplatin 130mg/m2 day1 Capecitabin 2,000mg/m2/day day1-15 XELIRI plus bevacizumab therapy Bevacizumab 7.5mg/kg day1 Irinotecan 200mg/m2 day1 Capecitabin 1,600mg/m2/day day1-15 Primary outcome(s): ORR; Overall response rate Study Design: Parallel Randomized

| 2622964 | ecrin-mdr-crc

Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment in patients with metastatic colorectal cancer(WJOG9216G)

Project description:Interventions: Arm A: FOLFIRI+Rmab treatment Rmab:8 mg/kg/day1 l-leucovorin (l-LV):200 mg/m2/day1 irinotecan (IRI): 180 mg/m2/day1 bolus 5-FU:400 mg/m2/day1 infusional 5-FU:2400 mg/m2/day1-3 Every 2 eeks Arm B: FOLFOXIRI+Rmab treatment Induction therapy: 8 courses (maximum of 12 courses) Rmab:8 mg/kg/day1 IRI:165 mg/m2/day1 l-LV:200 mg/m2/day1 oxaaliplatin (OX):85 mg/m2/day1 infusional 5-FU: 3200 mg/m2/day1-3 Every 2 weeks Maintenance therapy 5-FU/l-LV+Rmab, every 2 week Primary outcome(s): Objective response rate Study Design: Parallel Randomized

| 2641746 | ecrin-mdr-crc

Phase II study of XELIRI and High-dose bevacizumab as second-line therapy in patients with metastatic colorectal cancer

Project description:Interventions: XELIRI plus bevacizumab therapy Bevacizumab 10mg/kg day1 Irinotecan 150mg/m2 day1 Capecitabin 2,000mg/m2/day day1-8 Primary outcome(s): Progression Free Survival Study Design: Single arm Non-randomized

| 2623833 | ecrin-mdr-crc

Skin Toxicity Prevention Protocol with Panitumumab treatment for Metastatic Colorectal Cancer

Project description:Interventions: A group Panitumumab is administered intravenously in 6mg/kg by biweekly skin care+antibiotics Clarithromycin is administered orally twice a day B group Panitumumab is administered intravenously in 6mg/kg by biweekly skin care only Primary outcome(s): incidence rates of skin toxicity (>=Grade2) with or without antibiotics during the 6 weeks from the treatment started Study Design: Parallel Randomized

| 2626856 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data